FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2620641353> ?p ?o ?g. }

• W2620641353 endingPage "3183" @default.
• W2620641353 startingPage "3183" @default.
• W2620641353 abstract "Abstract Introduction Poly [ADP-ribose] polymerase 1 (PARP-1) has a central role in the repair of single-stranded DNA breaks, thus protecting the cell from genomic instability. Overexpression of PARP1 may lead a cell to apoptotic or necrotic death, defining the cell's fate. Genetic defects are important in the pathogenesis of myelodysplastic syndromes (MDS) and the role of PARP1 in the apoptotic pathways seems to be promising, since new agents targeting PARP1 are available. PARP1 expression has never been studied in MDS. Uridine-Cytidine Kinase (UCK) catalyzes the phosphorylation of uridine and cytidine as well as the pharmacological activation of several cytotoxic pyrimidine ribonucleoside analogues. The UCK family consists of two members, UCK1 and UCK2, both expressed in several tumor cell types. UCK2 in particular has been found to be expressed in pancreatic tumors, neuroblastoma and other malignant cells, but not in normal tissues, although it is normally expressed in human placenta. The selective expression of UCK2 in certain tumor cells enables selective malignant cell targeting with UCK2-dependent pyrimidine analogues, while sparing normal tissues. Aim Our aim was to detect PARP1, UCK1 and UCK2 mRNA in bone marrow samples of patients with MDS and investigate its correlations to the hematologic and prognostic characteristics of the patients. Patients and Methods Bone marrow samples were collected from patients with MDS. Quantification of PARP1 mRNA was performed by a SYBR-green based Real-Time PCR, and the results were expressed in correlation to those of the housekeeping gene of beta actin. Quantification of UCK1 and UCK2 was performed by a Real-Time PCR using specific oligonucleotides and TaqMan probes (Applied Biosystems, CA, USA) and all experiments were normalized to the housekeeping gene of glyceraldehyde-2-phosphate dehydrogenase (GAPDH). All reactions were performed on BIORADCFX96 (BIORAD Laboratories, CA, USA). PARP1 protein was also detected by western-blot using both simple films and the Azure c300 Chemiluminescent Western Blot Imaging System (Azure Biosystems, CA, USA). Results Fifty seven (57) patients with MDS were included in the study. The basic demographic and hematologic characteristics of the patients are shown in Table 1. The vast majority of the patients (92.9%) were treatment naïve. PARP1 mRNA levels were measured in 53 patients, while UCK1 and UCK2 mRNA levels were measured in all patients. The median PARP1 mRNA levels were 0.0259 (range 0.0003 - 0.6410) and showed a statistically significant correlation to the type of MDS (according to the WHO classification) (p=0.016) and to the IPSS score (p=0.001) (detailed results in Table). The lowest levels were observed in patients with RA (0.0053 vs 0.1477 for non-RA patients, p= 0.016), as well as in patients with low and intermediate 1 IPSS score (0.0107 vs 0.1831, p=0.01) that had almost 20 times lower PARP1 mRNA levels than patients with intermediate 2 and high risk MDS. The protein could only be detected in samples tested with the Azure c300 Chemiluminescent Western Blot Imaging System. The median value of PARP1 expression was 0.298 (0 - 1.625) and no correlations with the WHO classification or the IPSS were detected. To our knowledge, PARP1 detection by western blotting has never been performed in the past in MDS. Although both UCK1 and UCK2 were detected in the majority of the patients (40/57, 70.2% for UCK1 and 15/57, 73.7% for UCK2), no correlation was found between their levels and the type of MDS or the prognostic factors according to the IPSS or WPSS. The median levels were for UCK1 0.0202 (0 - 2.7431) and for UCK2 0.0169 (0 - 7.270). Detailed results are presented in Table 2. Conclusions The correlation of higher levels of PARP1 mRNA with higher risk MDS has never been reported in the past. This correlation, if confirmed by larger studies, may render PARP1 a prognostic factor for patients with MDS. Moreover, this result can lay the basis for the design of clinical trials evaluating the use of PARP1 inhibitors in patients with higher risk MDS. Although we didn't detect any correlation of UCK1 and UCK2 with the prognostic characteristics of MDS, their mere detection in clinical samples of patients with MDS is significant, since these molecules are not detected in every malignancy, but just in a subset of malignant diseases. This finding could be of value since targeted therapies are already available. Disclosures No relevant conflicts of interest to declare." @default.
• W2620641353 created "2017-06-09" @default.
• W2620641353 creator A5007089638 @default.
• W2620641353 creator A5014411816 @default.
• W2620641353 creator A5016064577 @default.
• W2620641353 creator A5024960041 @default.
• W2620641353 creator A5025768647 @default.
• W2620641353 creator A5036025144 @default.
• W2620641353 creator A5036771098 @default.
• W2620641353 creator A5051650967 @default.
• W2620641353 creator A5065816321 @default.
• W2620641353 creator A5070270344 @default.
• W2620641353 creator A5071786528 @default.
• W2620641353 creator A5077404231 @default.
• W2620641353 creator A5086734682 @default.
• W2620641353 date "2016-12-02" @default.
• W2620641353 modified "2023-09-27" @default.
• W2620641353 title "Expression of Poly [ADP-Ribose] Polymerase 1 (PARP-1) and Uridine-Cytidine Kinase (UCK) 1 and 2 in Myelodysplastic Syndrome" @default.
• W2620641353 doi "https://doi.org/10.1182/blood.v128.22.3183.3183" @default.
• W2620641353 hasPublicationYear "2016" @default.
• W2620641353 type Work @default.
• W2620641353 sameAs 2620641353 @default.
• W2620641353 citedByCount "0" @default.
• W2620641353 crossrefType "journal-article" @default.
• W2620641353 hasAuthorship W2620641353A5007089638 @default.
• W2620641353 hasAuthorship W2620641353A5014411816 @default.
• W2620641353 hasAuthorship W2620641353A5016064577 @default.
• W2620641353 hasAuthorship W2620641353A5024960041 @default.
• W2620641353 hasAuthorship W2620641353A5025768647 @default.
• W2620641353 hasAuthorship W2620641353A5036025144 @default.
• W2620641353 hasAuthorship W2620641353A5036771098 @default.
• W2620641353 hasAuthorship W2620641353A5051650967 @default.
• W2620641353 hasAuthorship W2620641353A5065816321 @default.
• W2620641353 hasAuthorship W2620641353A5070270344 @default.
• W2620641353 hasAuthorship W2620641353A5071786528 @default.
• W2620641353 hasAuthorship W2620641353A5077404231 @default.
• W2620641353 hasAuthorship W2620641353A5086734682 @default.
• W2620641353 hasConcept C104317684 @default.
• W2620641353 hasConcept C13576564 @default.
• W2620641353 hasConcept C150194340 @default.
• W2620641353 hasConcept C153911025 @default.
• W2620641353 hasConcept C181199279 @default.
• W2620641353 hasConcept C182979987 @default.
• W2620641353 hasConcept C203014093 @default.
• W2620641353 hasConcept C2776985229 @default.
• W2620641353 hasConcept C2778480876 @default.
• W2620641353 hasConcept C2779321679 @default.
• W2620641353 hasConcept C2780007613 @default.
• W2620641353 hasConcept C2781184954 @default.
• W2620641353 hasConcept C33922130 @default.
• W2620641353 hasConcept C502942594 @default.
• W2620641353 hasConcept C55493867 @default.
• W2620641353 hasConcept C82381507 @default.
• W2620641353 hasConcept C86803240 @default.
• W2620641353 hasConceptScore W2620641353C104317684 @default.
• W2620641353 hasConceptScore W2620641353C13576564 @default.
• W2620641353 hasConceptScore W2620641353C150194340 @default.
• W2620641353 hasConceptScore W2620641353C153911025 @default.
• W2620641353 hasConceptScore W2620641353C181199279 @default.
• W2620641353 hasConceptScore W2620641353C182979987 @default.
• W2620641353 hasConceptScore W2620641353C203014093 @default.
• W2620641353 hasConceptScore W2620641353C2776985229 @default.
• W2620641353 hasConceptScore W2620641353C2778480876 @default.
• W2620641353 hasConceptScore W2620641353C2779321679 @default.
• W2620641353 hasConceptScore W2620641353C2780007613 @default.
• W2620641353 hasConceptScore W2620641353C2781184954 @default.
• W2620641353 hasConceptScore W2620641353C33922130 @default.
• W2620641353 hasConceptScore W2620641353C502942594 @default.
• W2620641353 hasConceptScore W2620641353C55493867 @default.
• W2620641353 hasConceptScore W2620641353C82381507 @default.
• W2620641353 hasConceptScore W2620641353C86803240 @default.
• W2620641353 hasIssue "22" @default.
• W2620641353 hasLocation W26206413531 @default.
• W2620641353 hasOpenAccess W2620641353 @default.
• W2620641353 hasPrimaryLocation W26206413531 @default.
• W2620641353 hasRelatedWork W1875188462 @default.
• W2620641353 hasRelatedWork W1876426852 @default.
• W2620641353 hasRelatedWork W2073744682 @default.
• W2620641353 hasRelatedWork W2190095121 @default.
• W2620641353 hasRelatedWork W2270704840 @default.
• W2620641353 hasRelatedWork W2620641353 @default.
• W2620641353 hasRelatedWork W2755843571 @default.
• W2620641353 hasRelatedWork W2762572114 @default.
• W2620641353 hasRelatedWork W4205820893 @default.
• W2620641353 hasRelatedWork W4297860491 @default.
• W2620641353 hasVolume "128" @default.
• W2620641353 isParatext "false" @default.
• W2620641353 isRetracted "false" @default.
• W2620641353 magId "2620641353" @default.
• W2620641353 workType "article" @default.